GeminIQ Website Logo

Viewing RANI free

Subscribe for full history, 90+ metrics, screener, watchlist...

Rani Therapeutics Holdings, Inc.

RANI

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-06-30
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial
Subscriber-only column
Common Class A
----0-3334-03---
Common Class C
-0000000--0-
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value
5101941010445765
Accounts Receivable Net Current
222--10-----
Contract With Customer Asset Net Current
--00000---0-
Marketable Securities
493431006242626334356
Prepaid Expense Current
122111221223
Assets Current
57475351118303232415163
Property Plant And Equipment Net
111111256666
Operating Lease Right Of Use Asset
444445556611
Other Assets Noncurrent
00000000000-
Assets
615259101724374444545870
Liabilities And Stockhold…
Liabilities Current
Deferred Revenue
-------1----
Accounts Payable Current
110222121111
Accrued Liabilities And Other Liabilities
354232222324
Deferred Revenue Current
577---0-----
Long Term Debt Current
--0141515151512951
Operating Lease Liability Current
112111111111
Liabilities Current
1114131921202020171387
Deferred Revenue Noncurrent
002---0-----
Long Term Debt Noncurrent
--0026101417212428
Operating Lease Liability Noncurrent
223333444500
Liabilities
131617222629333838393236
Members Equity
Preferred Stock Value
000000000000
Additional Paid In Capital
1861681661141111071059790888683
Accumulated Other Comprehensive Income Loss Net Of…
-0-0000000-0-0-0-0
Retained Earnings Accumulated Deficit
-147-140-133-122-117-110-103-94-87-80-73-66
Stockholders Equity
392833-8-6-5363151318
Minority Interest
979-4-4-223371317
Liabilities And Stockholders Equity
615259101724374444545870
Common Class B
----24-024-024---
Preferred Stock Par Or Stated Value Per Share
000000000000
Preferred Stock Shares Authorized
202020202020202020202020
Preferred Stock Shares Issued
000000000000
Preferred Stock Shares Outstanding
000000000000

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
2026-23.15%-28.61%-28.33%---------
202516.18%11.00%9.54%-4.32%-9.94%241.46%-29.52%-38.33%-38.77%-11.48%0.00%-29.63%
2024-27.25%-49.74%-61.24%28.00%-13.60%-6.40%-17.87%-35.11%-40.85%-11.11%-51.03%-60.32%
2023------23.23%67.68%80.81%51.26%76.75%22.97%

Earnings Market Reaction data beyond 3 years is for subscribers only.

Unlock the full earnings market reaction history

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics
2026-06-30
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Metric history beyond 3 years is for subscribers only.

Unlock 17+ years of history across 90+ calculated metrics

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
5.31
3.40
4.21
0.26
0.54
0.88
1.50
1.60
1.93
3.09
6.36
8.61
Quick Ratio
5.21
3.28
4.08
0.22
0.50
0.82
1.41
1.50
1.86
2.96
6.08
8.24
Working Capital
45.89M
33.24M
40.65M
-14.19M
-9.55M
-2.35M
9.85M
12.16M
15.45M
28.02M
42.86M
55.88M
Leverage & Debt
Debt to Equity
0.33
0.58
0.41
-2.81
-4.67
-5.51
9.49
6.54
13.47
2.68
1.28
2.03
Interest Coverage TTM
-28.24
-17.01
-13.25
-12.19
-11.50
-10.96
-10.59
-9.95
-11.16
-12.30
-13.00
-15.56
Debt Ratio
0.21
0.31
0.29
2.18
1.54
1.22
0.90
0.87
0.87
0.73
0.56
0.51
Efficiency & Turnover
Asset Turnover TTM
0.13
0.08
0.03
0.04
0.04
0.03
0.02
0.00
0.00
0.00
0.00
0.00
Days Sales Outstanding TTM
152.83
152.15
456.42
-
-
182.50
-
-
-
-
-
-
Receivables Turnover TTM
2.39
2.40
0.80
-
-
2.00
-
-
-
-
-
-
Per Share Metrics
Diluted EPS TTM
-0.18
-0.20
-0.62
-1.02
-1.43
-1.63
-1.99
-2.51
-2.62
-2.85
-2.66
-1.46
Free Cash Flow Per Share TTM
-0.12
-0.10
-0.28
-0.42
-0.63
-1.03
-1.26
-1.38
-1.75
-1.90
-2.06
-2.15
Dividend Per Share TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Margin Metrics
Operating Profit Margin TTM
-675.80%
-1,092.96%
-2,345.99%
-3,727.67%
-4,106.17%
-4,274.42%
-5,186.19%
-
-
-
-
-
Net Profit Margin TTM
-685.34%
-1,143.17%
-2,507.65%
-3,966.50%
-4,367.17%
-4,545.25%
-5,504.28%
-
-
-
-
-
Growth Metrics
Net Revenue Growth (1Y)
306.42%
164.08%
58.85%
-
-
-
-
-
-
-
-
-100.00%
Net Income Growth (1Y)
-36.22%
-33.58%
-27.63%
-34.36%
-24.03%
-26.58%
-16.64%
93.81%
90.72%
195.60%
121.93%
-22.55%
EPS Growth (1Y)
-87.55%
-87.66%
-68.84%
-59.24%
-45.28%
-42.84%
-25.34%
71.74%
83.63%
186.58%
107.24%
-25.84%
Valuation Metrics
P/E TTM
-4.26
-3.65
-2.18
-0.49
-0.36
-0.77
-0.69
-0.86
-1.45
-1.09
-1.25
-1.49
P/B TTM
3.63
4.66
2.15
-2.95
-3.37
-7.88
11.17
10.79
35.28
5.57
3.33
3.17
P/S TTM
29.17
41.75
54.68
19.35
15.65
35.11
37.95
-
-
-
-
-
Market Cap
142.25M
132.30M
89.29M
23.22M
18.78M
42.13M
39.01M
62.29M
100.03M
80.97M
84.68M
55.58M
Enterprise Value
137.18M
122.45M
70.47M
32.12M
25.30M
52.44M
59.36M
85.81M
124.51M
103.03M
107.69M
79.43M
Calculated Values
Free Cash Flow TTM
-22.03M
-17.14M
-18.83M
-19.61M
-23.08M
-34.54M
-35.76M
-39.72M
-45.97M
-49.48M
-52.47M
-54.98M
Net Debt
-5.07M
-9.84M
-18.82M
8.89M
6.51M
10.31M
20.35M
23.53M
24.48M
22.06M
23.02M
23.85M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2025-10-23Purchase
Owner: Imran, Mir A
Title: -
Shares: 2,083,334
Price/Share: $0.61
Value: $1,270,833.74
Shares Owned: 2,083,334
Relationship: Director,TenPercentOwner
Ownership: Direct
2025-10-21Sale
Owner: South, Cone Investments L…
Title: -
Shares: 4,000,000
Price/Share: $2.77
Value: $11,080,000.00
Shares Owned: 2,379,194
Relationship: TenPercentOwner
Ownership: Indirect
2024-12-13Purchase
Owner: Mckinley, Kate
Title: Chief Business Officer
Shares: 17,960
Price/Share: $1.67
Value: $29,993.20
Shares Owned: 17,960
Relationship: Officer
Ownership: Direct
2024-12-09Purchase
Owner: Imran, Talat
Title: Chief Executive Officer
Shares: 10,296
Price/Share: $1.94
Value: $19,974.24
Shares Owned: 494,751
Relationship: Director,Officer
Ownership: Direct
2024-10-15Sale
Owner: South, Cone Investments L…
Title: -
Shares: 3,829,360
Price/Share: $2.90
Value: $11,105,144.00
Shares Owned: 8,302,194
Relationship: TenPercentOwner
Ownership: Indirect

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2026-03-31
23.58%
Inst. Shares: 42,451,184
Shares Outstanding: 179,996,000
2025-12-31
67.58%
Inst. Shares: 44,698,741
Shares Outstanding: 66,138,000
2025-09-30
8.33%
Inst. Shares: 3,867,850
Shares Outstanding: 46,444,000
2025-06-30
17.44%
Inst. Shares: 6,372,953
Shares Outstanding: 36,542,000
2025-03-31
10.58%
Inst. Shares: 3,537,627
Shares Outstanding: 33,440,000

Rani Therapeutics Holdings, Inc. (RANI) — SEC Financial Statements & Analysis

Rani Therapeutics Holdings, Inc. (RANI) is a pharmaceutical preparations company, incorporated in CA. Rani Therapeutics Holdings, Inc. trades on Nasdaq as: RANI. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Rani Therapeutics Holdings, Inc. reported a 306.42% year-over-year revenue growth, a Debt-to-Equity ratio of 0.33x, a Price-to-Sales (P/S) ratio of 29.17x (TTM), a Price-to-Book (P/B) ratio of 3.63x (TTM), at a market cap of $142.25M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y
306.42%
Debt To Equity
0.33x
P/S TTM
29.17x
P/B TTM
3.63x
Market Cap
$142.25M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Rani Therapeutics Holdings, Inc. in?

Rani Therapeutics Holdings, Inc. (RANI) operates in the Pharmaceutical Preparations industry.

What is RANI's market cap?

Rani Therapeutics Holdings, Inc. (RANI) has a market capitalization of $142.25M as of 2026-06-30.

What exchange does RANI trade on?

Rani Therapeutics Holdings, Inc. (RANI) trades on the Nasdaq.

Where is Rani Therapeutics Holdings, Inc. incorporated?

Rani Therapeutics Holdings, Inc. is incorporated in CA.

Wall Street's data.
Main Street's price.